Impact of Cochlear Radiotherapy Dose on Hearing Loss in Carcinoma Oropharynx Treated by Concurrent Chemoradiotherapy Using Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB -VMAT)
- 6 March 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 77 (4) , 1727-1733
Abstract
This study evaluates the impact of reduction of radiotherapy dose received by cochlea on hearing loss in oropharyngeal cancer patients treated by concurrent cisplatin chemoradiotherapy using simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT). Sixty ears were evaluated in this prospective non blinded randomized trial. The study group (n=30) was treated with concurrent chemoradiotherapy using Image Guided Radiotherapy with Simultaneous Integrated Boost-Volumetric Modulated Arc technique. The matched control group (n=30) received concurrent chemoradiotherapy using 3D conformal radiotherapy (3DCRT). Concurrent chemotherapy was given to all patients with injection Cisplatinum 100 mg/m2 on D1,22&43 along with radiotherapy. Baseline hearing evaluation was done using puretone, impedence and high frequency audiometry. The tests were repeated at 6 months follow up to evaluate hearing loss. The mean radiotherapy dose received by the right and left cochlea in the 3DCRT and SIB-VMAT techniques was 38.99±4.78 versus 6.97±6.09 Gy (mean±SD) (p=0.001) and 38.59±5.10 versus 6.79±5.76 Gy (p=0.001). At 6 months of follow up sensorineural hearing loss was observed in 66.7 versus 0% (p=0.001) and 86.7 versus 6.7% (p=0.001) in the right and left ear in the 3DCRT and SIB-VMAT groups.High risk PTV 66 volume more than 300 cc was associated with a higher risk of hearing loss with odds ratio of 6.05 (95% CI 0.54-67.53) and 4.41(95% CI 0.52-37.16) in right and left ear. Age more than fifty years was associated with significant hearing loss in the right ear with an odds ratio of 12.56 (95% CI 0.84-187.87) (p=0.02) and 7.38 (95% CI 0.74-73.59) for the left ear. The study shows that reduction in radiotherapy dose received by cochlea is an independent determinant in reducing ototoxicity in the setting of concurrent single agent cisplatin chemotherapy. High risk PTV volume more than 300 cc was associated with a significant increase in hearing loss and PTV 66 volume emerged as a predictive factor for treatment related hearing loss.Keywords
This publication has 19 references indexed in Scilit:
- Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2020
- Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literatureHead & Neck, 2014
- Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With RadiotherapyJAMA Otolaryngology–Head & Neck Surgery, 2010
- Radiation Therapy and Hearing LossInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Mechanisms of cisplatin-induced ototoxicity and preventionHearing Research, 2007
- Ototoxicity after radiotherapy for head and neck tumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinomaCancer, 2006
- Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinomaRadiotherapy and Oncology, 2004